Drug Profile
Plitidepsin - PharmaMar
Alternative Names: Aplidin; Aplidine; DDB; Dehydrodidemnin B; PM90001Latest Information Update: 27 Apr 2023
Price :
$50
*
At a glance
- Originator PharmaMar
- Developer Boryung Pharmaceutical; PharmaMar
- Class Anti-inflammatories; Antineoplastics; Antivirals; Depsipeptides; Lactones
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Peptide elongation factor 1 inhibitors; Protein synthesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma; Multiple myeloma; Peripheral T-cell lymphoma
Highest Development Phases
- Marketed Multiple myeloma
- Phase III COVID 2019 infections
- Phase II Non-Hodgkin's lymphoma; T-cell lymphoma; Urogenital cancer
- No development reported Liposarcoma; Malignant melanoma; Myelofibrosis; Solid tumours
- Discontinued Leukaemia; Prostate cancer
Most Recent Events
- 24 Apr 2023 Launched for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (IV) before April 2023
- 20 Apr 2023 PharmaMar expects approval of the phase II NEREIDA trial for COVID-2019 infections in other countries
- 20 Apr 2023 PharmaMar reports approval of the phase II NEREIDA trial for COVID-2019 infections in Spain, France, Italy, Greece, Hungary, Poland and Portugal (IV)